If you have atopic dermatitis, certain fabrics and clothing styles can trigger intense irritation and itch. Here’s how to dress right to protect your hypersensitive skin. When you have atopic ...
Emma Guttman, MD, PhD, discusses the promising potential of rocatinlimab in targeting the OX40-OX40 ligand pathway for atopic dermatitis treatment. Trial investigator Emma Guttman, MD, PhD, chair of ...
Megan Rogge, MD, Associate Professor of Dermatology at McGovern Medical School, UTHealth Houston, details the varied conversations with patients that are often necessary before inititating treatment ...
The approval is the first topical Janus kinase (JAK) inhibitor for the short-term, noncontinuous chronic treatment of mild-to-moderate AD in nonimmunocompromised children (age 2 years and older) whose ...
Hosted on MSN
This is what causes doubts in women’s minds
An insight into the key factors that trigger uncertainty and second thoughts in women’s minds. Trump Rips Fox News Poll — Clashes with Interviewer ‘This is a great result’: TikTok ‘goes American’ ...
MONDAY, Sept. 29, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opzelura cream 1.5 percent (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD). The ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Incyte Corporation’s (NASDAQ:INCY) announced Opzelura (ruxolitinib) cream 1.5% for the short-term and non-continuous chronic treatment ...
Brussels (Belgium), September 18, 2025 – 07:00 (CEST) – UCB, a global biopharmaceutical company, today announced new 12-week efficacy and 18-week safety data from the Phase 1/2a first-in-patient trial ...
Nearly 50% of survey respondents living with atopic dermatitis (AD) report a severe impact on their quality of life, yet 79% of patients surveyed find their current treatment approaches ineffective. 1 ...
Chlamydia is a prevalent sexually transmitted infection. World Health Organisation reports millions of new STI cases annually. Chlamydia trachomatis is a common cause. Many infected individuals show ...
PARIS — The anti-OX40 monoclonal antibody rocatinlimab produced clinically meaningful improvements in adults with moderate-to-severe atopic dermatitis both as monotherapy and when used with topical ...
LEO Pharma A/S, a global leader in medical dermatology, today announced a late-breaking post hoc analysis of the European Academy of Dermatology and Venereology (EADV) Congress in Paris. The results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback